IIPRMEDIUM SIGNALFINANCIAL10-K

IIPR reported declining financial performance across key metrics while significantly reducing its cash position and expanding beyond cannabis into life sciences investments.

The company's revenue decline of 13.8% coupled with reduced profitability suggests potential headwinds in its core cannabis real estate business. The dramatic 67.5% reduction in cash reserves to $47.6M raises questions about liquidity management and capital allocation strategy, particularly concerning given the company's real estate acquisition model.

Comparing 2026-02-24 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

IIPR experienced broad-based financial deterioration with revenue falling 13.8% to $266.0M and net income declining 26.9% to $118.2M, indicating margin compression. The company's cash position dropped substantially from $146.2M to $47.6M while total liabilities increased 18.3% to $522.9M. Operating cash flow also weakened by 23.3% to $198.2M, reflecting the overall challenging operating environment and potentially constraining the company's ability to pursue new acquisitions without external financing.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-67.5%
$146.2M$47.6M

Cash declined 67.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-26.9%
$161.7M$118.2M

Net income declined 26.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-26.3%
$168.3M$124.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-23.3%
$258.4M$198.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Liabilities
Balance Sheet
+18.3%
$442.0M$522.9M

Liabilities increased 18.3% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
-13.8%
$308.5M$266.0M

Revenue softened 13.8% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-21
ADDED
As of February 24, 2026, there were 28,135,865 shares of common stock outstanding.
We have acquired and expect to continue to acquire our cannabis properties through sale-leaseback transactions and third-party purchases.
These properties are generally leased, and we expect to continue leasing them on a triple-net lease basis, pursuant to which the tenant is responsible for all aspects of and costs related to the property and its operation during the lease term, including structural repairs, maintenance, real estate taxes and insurance.
Outside of the cannabis sector, our leases may include different lease structures that do not require tenants to assume all property-related expenses.
In addition to our cannabis-related real estate portfolio, we also have financial investments in the life science industry and intend to actively pursue acquisitions of properties within that sector as a key component of our growth strategy.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were 28,331,833 shares of common stock outstanding.
We have acquired and intend to continue to acquire our properties through sale-leaseback transactions and third-party purchases.
We have leased and expect to continue to lease our properties on a triple-net lease basis, where the tenant is responsible for all aspects of and costs related to the property and its operation during the lease term, including structural repairs, maintenance, real estate taxes and insurance.
2024 Business Update Investments During 2024, we acquired two new properties and made additional investments into existing properties under development or redevelopment.
As of December 31, 2024, we owned 109 properties comprising an aggregate of 9.0 million rentable square feet (including 666,000 rentable square feet under development/redevelopment) in 19 states.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →